CD8A and neoplasm: Importantly, although this maneuver led to complete regression of established tumors in a large percentage of mice, minimal benefit was observed when IFNα was administered either before or concomitantly with combination therapy, as the loss of phagocytic capacity that accompanied CD8α+ DC maturation at these early times limited the ability of these cells to acquire tumor Ag later released as a result of therapy.